Peptide storage and stability, the practical, evidence-grounded version

Key takeaways

• Lyophilized peptide is stable for months to years; reconstituted peptide degrades much faster because hydrolysis dominates in solution.
• Approved peptide product storage/in-use windows: the single-dose Wegovy pen may be kept at room temperature (up to 30 C) for up to 28 days before use, then is discarded after one dose; Ozempic in-use up to 56 days at room temperature or refrigerated; Mounjaro / Zepbound permit room-temp excursions to 30 C up to 21 days.
• Peptide degradation pathways: hydrolysis (rate rises with temperature and pH extremes), deamidation (Asn / Gln residues), oxidation (Met / Cys / Trp / Tyr / His), aggregation, disulfide scrambling.
• Bacteriostatic water for injection contains 0.9 percent benzyl alcohol as a preservative; appropriate for multi-dose vials. Sterile water has no preservative; for single-use only.
• A meaningful certificate of analysis reports peptide purity (HPLC area percent, target ≥95 percent), identity confirmation (mass spec), and endotoxin level (target <1 EU per dose).

Lyophilized vs. reconstituted, why it matters

A lyophilized peptide is a freeze-dried solid. The water is gone, which means hydrolysis (the dominant chemical degradation pathway for most peptide bonds in solution) is dramatically slowed. Once reconstituted, the same peptide is now sitting in water, and its half-life shortens. That is why product labels for parenteral peptides distinguish a long shelf life as a powder from a much shorter in-use stability after reconstitution.

FDA-approved peptide drug labels make this concrete. Approved GLP-1 analogs like semaglutide and tirzepatide carry refrigerated in-use windows on the order of weeks once the pen is pierced, and explicit storage conditions in the prescribing information . Compounded products do not necessarily inherit the same in-use stability, and the FDA has flagged dosing-error risks tied to mislabeled compounded GLP-1 products .

The degradation chemistry, in plain language

Peptides degrade by several distinct chemical pathways, each with different sensitivity to storage conditions:

• Hydrolysis: the peptide bond cleaves in the presence of water; rate increases with temperature and at pH extremes. Asparagine and glutamine residues are most susceptible. This is the dominant degradation pathway for reconstituted peptides.
• Deamidation: asparagine and glutamine residues lose their amide group, becoming aspartate and glutamate. The change is small in molecular-weight terms but can alter receptor binding and aggregation behavior.
• Oxidation: methionine, cysteine, tryptophan, tyrosine, and histidine residues oxidize in the presence of air or light. Methionine oxidation is the most common and is accelerated by transition-metal contamination (iron, copper).
• Aggregation: physical association of peptide molecules driven by hydrophobic interactions, surface adsorption, or freeze-thaw stress. Aggregates can be immunogenic and may reduce active-monomer concentration.
• Disulfide scrambling: peptides with multiple cysteine residues (insulin, oxytocin, vasopressin) can scramble disulfide bonds in solution, producing misfolded or inactive species.

Diluents: bacteriostatic water, sterile water, and pH

Bacteriostatic water for injection contains 0.9 percent benzyl alcohol as a preservative. The benzyl alcohol limits microbial growth across multiple draws, which is the point. Sterile water for injection has no preservative and is intended for single-use reconstitution. The choice depends on the product label and the intended dosing pattern, and bacteriostatic water carries population-specific cautions, including pediatric use, that are documented in the prescribing information .

Some peptides are pH-sensitive in solution. Aggregation, deamidation, and oxidation rates depend on pH and ionic strength, which is why approved peptide products specify diluent identity and concentration on the label rather than leaving it to the user.

Light, temperature, and freeze-thaw cycles

• Light: photo-oxidation of methionine, tryptophan, tyrosine, and histidine residues is well characterized in protein and peptide chemistry. Amber vials and opaque shipping help. Most labeled peptide products specify protection from light.
• Temperature: most reconstituted peptides degrade faster at room temperature than at refrigerator temperature. Approved products specify storage between 36 and 46 degrees Fahrenheit (2 to 8 degrees Celsius) for in-use stability. Most also tolerate brief excursions (often up to 30 degrees C for limited periods) per labeling.
• Freeze-thaw: repeated freezing and thawing of solution can drive aggregation. For lyophilized solid powder, this is much less of an issue because there is no liquid water to nucleate ice damage. Some labels (Wegovy, Ozempic) explicitly prohibit freezing of the in-use pen.
• Agitation: shaking liquid peptide preparations creates air-water interfaces that promote denaturation and aggregation. Most labels recommend gentle inversion rather than shaking during reconstitution.

Named in-use windows from approved labels

• Wegovy (semaglutide): refrigerated 2-8 C between uses; in-use pen up to 28 days; brief room-temperature excursions to 30 C permitted within the 28 days .
• Ozempic (semaglutide): refrigerated 2-8 C; in-use pen up to 56 days at room temperature (15-30 C) or refrigerated .
• Mounjaro / Zepbound (tirzepatide): refrigerated 2-8 C; brief room-temperature excursions to 30 C up to 21 days permitted .
• Egrifta WR (tesamorelin): unmixed vial at room temperature, stored away from light; reconstituted vial discarded after the labeled in-use period.
• Apidra (insulin glulisine): in-use vial up to 28 days at room temperature below 25 C, refrigerated up to 28 days.
• Lyophilized research peptides (BPC-157, TB-500, Ipamorelin): no FDA label; community-cited in-use windows are 30 days refrigerated for reconstituted vials, with much longer windows (months to years) for unmixed lyophilized powder at refrigerated or frozen storage.

Compounded cold-chain reality

Compounded peptide preparations from 503A pharmacies typically ship in insulated boxes with cold packs by overnight courier. The actual temperature trace from compounding pharmacy to user can include several handoffs (pharmacy to courier, courier to local hub, hub to delivery vehicle, vehicle to doorstep). Excursions above the labeled refrigerated range are common, particularly in summer climates and on packages left at the doorstep before refrigeration.

Some 503A pharmacies include a temperature-indicator strip in shipments. Most do not. Users have no easy way to verify that the cold chain was preserved end-to-end. Practical mitigation: refrigerate immediately on receipt, inspect for crystallization or cloudiness, and discontinue use if the vial appearance is abnormal.

How to read a certificate of analysis (CoA)

A certificate of analysis from a peptide manufacturer typically reports peptide purity (HPLC area percent), peptide content (mass spec or amino acid analysis), water content (Karl Fischer), residual TFA (if synthesized using TFA), endotoxin level, and identity confirmation by mass spec. For an FDA-approved drug product, full CMC documentation goes beyond CoA into batch-release testing, sterility, and stability indicating assays.

What matters for a buyer: peptide purity 95 percent or higher (per HPLC), identity confirmed by mass spec at the expected molecular weight, endotoxin below 1 EU per dose. Vendors that do not provide a CoA, or that provide a CoA without batch-specific data, are providing less assurance than the document suggests.

What the published stability literature shows

There is a peptide stability literature, but it is uneven. For approved products, full chemistry, manufacturing, and controls (CMC) data are summarized in the FDA review documents available through the agency's drug-approval system . For research peptides, public stability data are often limited to the manufacturer's certificate of analysis. PubMed indexes a wide range of formulation papers, and a search for the specific peptide plus 'stability' is the right starting point .

The published GLP-1 stability literature is more robust than for any research peptide. Tirzepatide and semaglutide formulation papers in journals like the Journal of Pharmaceutical Sciences cover thermal stress, freeze-thaw, agitation, and aggregation kinetics .

Editorial summary

Lyophilized peptide is stable. Reconstituted peptide is not. The labeled in-use windows from approved products are the most reliable real-world reference. Compounded products do not inherit those windows, and the cold-chain reality of overnight shipping introduces uncertainty that most users cannot verify.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.